U.S. Markets close in 51 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,432.74 | -199.64 | -1.72% |
| NASDAQ | 2,301.27 | -24.61 | -1.06% |
| S&P 500 | 1,263.06 | -19.13 | -1.49% |
| Day Low 09:47 AM EDT | 45.31 | |
|---|---|---|
| Day High 01:26 PM EDT | 46.47 |
|
| Range | 1.16 | |
| Volume | 1.47 M | |
| 30-Day Avg. Vol. | 1.47 M |
|
| Difference | 0.35% | |
| Market Cap. | 3.94 B | |
| Change | -20.76 M | |
| Shares Out. | 86.54 M | |
| Percent Traded | 1.71% | |
| Revenue | 590.83 M | |
| Earnings | 39.79 M | |
| EPS (TTM) | -0.53 |
| 52-Wk Low 8/9/07 | 30.34 | |
|---|---|---|
| 52-Wk High 4/23/08 | 49.18 |
|
| Range | 18.84 | |
| Prev. Close 7/23/08 | 45.88 | |
| Today's Open | 45.54 | |
| Change | -0.74% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.8473 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | 35.00 |
ImClone Systems has got it in for the big "C." The biotechnology firm is focused on developing monoclonal antibody therapies that treat various forms of cancer. Its only product on the market is Erbitux, ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.25 12/31/07 | -0.23 12/31/07 |
-0.48
Missed
|
| Last Quarter | 0.339 3/31/08 | 0.33 3/31/08 |
-0.009
Missed
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 162.64 M | 590.83 M |
| Gross Profit | 138.55 M | 507.80 M |
| Operating Income | 42.50 M | 161.45 M |
| Net Income | -55.90 M | 39.80 M |
Real-Time Quote
